Document rxkLvxk9vgrM2y4v3R5j0noGa
TRADE SECRET
Study Title H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
Supplement No. 1
Laboratory Project ID: DuPont-4182
AR226-3217
AUTHOR: Carol Finlay, B.A. STUDY COMPLETED ON: September 5, 2000
SUPPLEMENT NO. 1 COMPLETED ON: January 11, 2002
PERFORMING LABORATORY:
E.I. du Pont de Nemours and Company Haskell Laboratory for Health and Environmental Sciences Elkton Road, P.O. Box 50 Newark, Delaware 19714-0050
C-^ WORK REQUEST NUMBER: I------\ * SERVICE CODE NUMBER:|^^B\
Page 1 of 40
Company Sanitized. Does not contain TSCA CBI
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
CERTIFICATION
We, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study.
Reviewed by:
T^W^L^t- 'Paul M. Hitldcrliter, Ph.D.
Postdoctoral Fellow
Y Reviewed bytC^.^O^L ^. ^VX <s66t^^ Judith C. Stadlcr, PhJS.. DAA.T. Director
Issued by Study Director:
iOLA^ ^CVUL^
Carol KniBy, B-A(
Staff Scientist
^g-^.-2*-^.
Date
M -Ttf7t/-^^3L
Date
2L-4jLiL_^0^ (jDatc
Comoany Sanil^ed. n^s ,,<,? f.wWn TSCA CBI
-2-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
U^^R '^y
TABLE OF CONTENTS
Page
CERTIFICATION........................................................................................................................^
LIST OF TABLES .........................................................................................................................4 LIST OF FIGURES .......................................................................................................................4 LIST OF APPENDICES...............................................................................................................4 STUDY INFORMATION .............................................................................................................5 STUDY PERSONNEL...................................................................................................................? REASON FOR SUPPLEMENT NO. 1 ........................................................................................8
SUMMARY...................................................................................................................................^
MATERIALS AND METHODS ................................................................................................10
RESULTS AND DISCUSSION ..................................................................................................10
A.
Liver
10 Weights....................................................................................................................
1. Test Substance........................................................................................................................................ 10
2. Positive Controls....................................................................................................................................10
B. Liver Fluorine Data............................................................................................................11
1. Positive Controls ....................................................................................................................................11
2. TestSubstance........................................................................................................................................ll
CONCLUSIONS ..........................................................................................................................11
TABLES........................................................................................................................................12
FIGURES......................................................................................................................................16
APPENDICES ..............................................................................................................................22
Company Sanitized. Does not contain TSCA CBI
-3-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
LIST OF TABLES
Page
1. MEAN BODY AND LIVER WEIGHTS (g) .......................................................................................................13 2. MEAN LIVER FLUORINE LEVELS..................................................................................................................15 3. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE.................................................. 15
LIST OF FIGURES
Page
1. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND NEGATIVE
CONTROLS.........................................................................................................................................................17
2. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND POSITIVE
CONTROLS.........................................................................................................................................................18
3. COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCENTRATION FOR H-24159 AND NEGATIVE CONTROLS................................................................ 19
4. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE..................................................20 5. COMPARISON OF MEAN BLOOD AND MEAN LIVER FLUORINE CONCENTRATION
NORMALIZED TO DOSE..................................................................................................................................21
LIST OF APPENDICES
Page
A. INDIVIDUAL FINAL BODY WEIGHTS, LIVER WEIGHTS, AND RELATIVE LIVER TO BODY
WEIGHT.............................................................................................................................................................^
B. INDIVIDUAL FLUORINE LEVELS..................................................................................................................34
Company Sanitized. Does not contain TSCA CB1
.4-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
STUDY INFORMATION TEST SUBSTANCE:
Substance Tested:! Synonyms/Codes:
H-24159 Haskell Number: 24159
Composition
DuPont-4182 Supplement No. 1
Known Impurities
POSITIVE CONTROL:
Substance Tested: Potassium perfluoroalkyi sulfonate
Synonyms/Codes: H-24019
Haskell Number: 24019
Company Sanitized. Does not contain TSCA CB1
-5-
STUDY INFORMATION (Continued)
Composition:!
Known Impurities:
POSITIVE CONTROL:
Substance Tested: Octanoic acid, pentadecafluoro-, ammonium salt Synonyms/Codes: H-24020
Perfluorooctanoate, ammonium salt APFO Ammonium perfluorooctanoate Haskell Number 24020 Composition!
Known Impurities:
Sponsor:
E. I. du Font de Nemours and Company Wilmington, Delaware 19898
U.S.A.
Study Initiated/Completed: April 30, 1999 / (see report cover page)
m-Life Initiated/Completed: July 11, 1999 / October 12,1999
Company Sanitized. Does not contain TSCA CB?
-^-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
STUDY PERSONNEL
Study Director: Management:
Primary Technician:
Carol Finlay, B.A. Judith C. Stadler, Ph.D., D.A.B.T. Richard P. Mathena
Liver Fluorine Data Analysis: Paul M. Hinderliter, Ph.D. Management: Matthew S. Bogdanffy, Ph.D., D.A.B.T.
Toxicology Report Preparation: Wanda P. Dinbokowitz
Laboratory Veterinarian: Wanda L. West, D.V.M., A.C.L.A.M.
Company Sanitized. Does nol contain TSCA CBt
.7-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
REASON FOR SUPPLEMENT NO. 1
The purpose of this supplement is to present the results from analysis of selected liver samples from rats treated with the test substance (H-24159), 2 positive controls (H-24019 and H-24020), and 2 negative controls (corn oil and corn oil/acetone).
Company Sanitized. Does no* contam TSCA CIS 8-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
SUMMARY
The objective of this study was to evaluate the potential for H-24159, when administered by gavage, to be absorbed and to accumulate in a mammalian system. Six groups of 5 male Crl:CD(SD)IGS BR rats each were given 35 mg/kg/day of H-24159. The test substance was administered to one group of 5 rats for 5 consecutive days and to 5 groups for 10 days. On
selected days (5,10,13,24, 52,94) 5 rats per group were euthanized and the blood and livers
were collected. Livers were weighed and those collected on study days 10 and 94 were analyzed for total fluorine. This supplement includes liver weight data and the results of total fluorine analyses in liver. Additionally, 2 negative controls, corn oil and corn oiVacetone (80:20), and 2 positive controls, H-24019 (10 mg/kg/day) and H-24020 (20 mg/kg/day), were tested as described for H-24159.
The mean relative liver weights (liver/body weight) of rats dosed with the test substance, H-24159, were similar to the negative controls. On day 10, the mean relative liver weight of rats dosed with the positive control H-24019 was up to 27% higher than the negative controls. By day 94, the mean relative liver weight was up to 28% higher than the negative controls. In rats given H-24020, the mean relative liver weight was up to 75% higher than the negative controls. By day 94, the weights were similar.
The concentration of fluorine in the livers from rats dosed with the test substance, H-24159, was
1617.20 iJiM. equivalents on day 10 and 91.00 ^M equivalents on day 94. The liver
concentrations for the positive control H-24019 were approximately 3x higher (day 10) and approximately 13x higher (end of study) than H-24159. The liver concentrations for the test substance, H-24159, were approximately 1.4x higher (day 10) and approximately 8x higher (end of study) than the positive control H-24020.
The pM equivalents of fluorine in the livers from rats dosed with the test substance, H-24159,
were higher than levels in the blood.
Under the conditions of this study, there was some absorption and retention of fluorine in the liver from rats dosed with H-24159. Fluorine levels in the liver were lower than levels in rats dosed with the positive control H-24019. However, fluorine levels in the livers from rats dosed with the test substance were higher than levels in rats dosed with the positive control H-24020. Liver weights were not affected in rats dosed with the test substance.
Company Sanitized. Does nc? contain TSCA CBI
9-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
MATERIALS AND METHODS
Blood and livers were collected on days 5,10,13,24, 52, and 94. The livers were weighed.
Only the test day 10 and 94 livers were analyzed for total fluorine. These time points provided sufficient data to determine the accumulation and persistence of fluorine in the liver. See the original report for details of the analysis.
RESULTS AND DISCUSSION
A. Liver Weights (Table 1, Figures 1-3, Appendix A)
As with the body weights, comparison of absolute liver weights was complicated by the fact that there was a difference in age between rats dosed with the test substance and those dosed with the H-24019 positive control and the corn oiLacetone negative control. Therefore, liver weights relative to total body weight are presented for comparison for all rats.
1.
Test Substance
The mean relative liver weights of rats dosed with the test substance, H-24159, were similar to the negative controls.
2.
Positive Controls
The mean relative liver weight of rats dosed with one of the positive controls, H-24019, was 14% higher on day 10 than the liver weight of rats dosed with the test substance, H-24159. The liver weights of rats dosed with H-24019 were 11-36% higher during the recovery period than the liver weights of rats dosed with the test substance. The mean relative liver weight of rats dosed with H-24020, the other positive control, was 57% higher on day 10 than the liver weight of rats dosed with H-24159. On days 13 and 24 (recovery), the mean relative liver weights of rats dosed with H-24020 were 60 or 24% higher than the liver weights of rats dosed with H-24159. On days 52 and 94, the weights were similar.
The mean relative liver weight of rats dosed with H-24019 was up to 27% higher at day 10 than the negative control groups. By day 94, the mean relative liver weight of rats dosed with H-24019 was up to 28% higher than the negative controls. The mean relative liver weight of rats dosed with H-24020 was up to 75% higher at day 10 than the negative controls. The mean relative liver weights of rats dosed with H-24020 began to decrease during the recovery period and were similar by test day 94 to the negative controls.
Therefore, liver weights of rats dosed with the test substance, H-24159, were not affected.
"~l^~ Company Sanitized. Does not contain TSCA CBl
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
B. Liver Fluorine Data (Tables 2 and 3, Figures 3 - 5, Appendix B)
1.
Positive Controls
The positive controls were H-24019 and H-24020. The concentrations of fluorine in the livers on
day 10 from rats dosed with the positive control materials were 5045.85 and 1127.25 /iM
equivalents for H-24019 and H-24020, respectively. By day 94, the concentrations were 1190.15 and 10.72 j^M equivalents.
2.
Test Substance
Levels of total fluorine in livers from rats dosed with the test substance, H-24159, were lower than the levels in livers from rats dosed with the positive control H-24019 but higher than the levels in livers from rats dosed with the positive control H-24020. The total fluorine concentration in the liver from rats dosed with H-24159 was 1617.20 pM equivalents at day 10 and 91.00 flM equivalents at day 94. For the positive control H-24019, the liver concentrations were approximately 3x higher (day 10) and approximately 13x higher (end of study) than H-24159. The liver concentration was approximately 1.4x higher on day 10 in rats dosed with the test substance than in rats dosed with the positive control H-24020. On day 94, the concentration was approximately 8x higher in rats dosed with H-24159 than in rats dosed with H-24020.
The <xM equivalents of fluorine in the liver were higher than levels in the blood.
CONCLUSIONS
Under the conditions of this study, there was some absorption and retention of fluorine in the liver from rats dosed with H-24159. Fluorine levels in the liver were lower than levels in rats dosed with the positive control H-24019. However, fluorine levels in the livers from rats dosed with the test substance were higher than levels in rats dosed with the positive control H-24020. Liver weights were not affected in rats dosed with the test substance.
Company Sanitized. Does not contain TSCA CW
ll-
TABLES -12- Comoany Sanitized. Does not contain TSCA CB1
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
Test Days
5 10 13 24
52 94
TABLE 1
MEAN BODY AND LIVER WEIGHTS (g)
CORN OIL (NEGATIVE CONTROL)
Abs olute
Body Weight
Liver Weight
259.3
12.620
311.1
15.861
322.9
14.906
391.2
16.635
464.7
17.240
557.8
20.118
Mean Relative Liver Weight(% of Body Weight)
0.049 0.051 0.046 0.043 0.037 0.036
Test Days 5 f 10
13
24 52 94
CORN OIL:ACETONE (NEGATIVE CONTROL)
_________Absolute________
Body Weight____Liver Weight
13-1131^.41
1i-3'i.^63i'2t
356.5
15.597
377.6
17.715
423.5
17.172
527.6
21.275
567.8
18.447
Mean Relative Liver Weight(% of Body Weight)
0r\.0rv4/i3o 0.044 0.047 0.041 0.040 0.032
Test Days
5 10 13 24 52 94
H-24019 (POSITIVE CONTROL)
Absolute
Body Weight___Liver Weight
306.6
15.456
310.1
17.336
344.8
22.049
387.9
21.313
438.1
19.826
597.9
24.455
Mean Relative Liver Weight(% of Body Weight)
0.050 0.056 0.064 0.055 0.045 0.041
-13- Company Sanitized. Does not contain TSCA CT3T
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
Test Days
5 10 13
24 52 94
TABLE 1 (Continued)
MEAN BODY AND LIVER WEIGHTS (g)
H-24020 (POSITIVE CONTROL)
Abs olute
Body Weight
Liver Weight
244.8
17.052
284.4
21.944
289.1
21.780
370.3
20.619
456.7
17.713
538.7
18.205
Mean Relative Liver Weight(% of Body Weight)
0.070 0.077 0.075 0.056 0.039 0.034
Test Days 5 10
13 24
52 94
H-24159 (TEST SUBSTANCE)
__B_o_d_y_W_e_igAhbt_s_o_l_uLtieve_r_W_e_ig_h_t __
265.0
13.327
303.3
14.764
323.0
15.184
402.6
18.144
488.3
17.842
576.4
21.086
Mean Relative Liver Weight(% of Body Weight)
0.050 0.049 0.047 0.045 0.037 0.037
Company Sanitized. Does not contain TSCA CB1 14-
TABLE 2 MEAN LIVER FLUORINE LEVELS
Test Days
10 94
Negative Controls
Corn Oil (ppm)
Corn Oil:Acetone
(ppni)
<0.2 0.63
<0.5
I3
Positive Controls
H-24019 (ppm)
328.18 (19.3)" 77.56 (10.1)
H-24020 (ppm)
155.76 (29.2) 1.68 (0.3)
a One value. Four of the values were below the level of detection (LOD).
b Standard deviation is in parentheses.
Test Substance
H-24159 (ppm)
90.5 (8.45) 5.3 (1.10)
TABLE 3
MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE
Test Days
10
94
Positive Controls
H-24019
H-24020
liM F Equivalents
5045.85 (296.91)3
/zM F Equivalents 1127.25 (211.37)
1190.15 (156.05)
10.72 (2.14)
a Standard deviation is in parentheses.
Test Substance
H-24159
^M F Equivalents
1617.20 (151.34) 91.00 (19.76)
-15- Company Sanitized. Does not contain TSCA CBI
FIGURES
-16-
Company Sanitized. Does no< conla'n TSCA CBI
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
FIGURE 1 COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND NEGATIVE CONTROLS
0.06
0.05
*j
S-
0
BQ
0.04
*J
^ 0.03
0.02
0.01
0.00
-17-
Company Sanitized. D
\ H-24159: Biopersistence Screening
10-Dose Oral Gavage Study in Rats
FIGURE 2 COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND POSITIVE CONTROLS
-18-
Company SanFffeed. Do
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
FIGURES COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCEN
FOR H-24159 AND NEGATIVE CONTROLS
^ j
0.01
Day 10
Day 13
Day 94
Day 10
S Corn Oil (Negative Control) Corn OiLAcetone (Negative Control) D H-24159 (Test Substance)
Company Sanitized. Doe 19-
S4159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
FIGURE 4 MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE
6000
5000
4000
I
II 3000
to
al.
2000
1000
Day 10
Day 94
Company Sanitized. Do 20-
1-74159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
FIGURES COMPARISON OF MEAN BLOOD AND MEAN LIVER FLUORINE CONCENTRATION NORMAL
6000
5000
a
I
S w 3000
a
i
V
M
s
2000
1000
Blood / Liver
Blood / Liver
-21-
Blood / L company Sanitized.
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
APPENDICES
-22-
Company Sanitized. Does not contain TSCA CB1
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
APPENDIX A Individual Final Body Weights, Liver Weights, and Relative Liver to Body Weight
-23-
'"impany Sanitized. Does no! contain TSCA CB1
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
CORN OIL (NEGATIVE CONTROL)
iNDryiDUAL FINAL BODY WEIGHTS (g), LIVER WEIGHTS (g ) , AND RELATIVE LI\fER TO BODY WEK3HT OF MALE RATS
Animal
Number 627789
627801
627805
627810
627818
Final
Body Wt. 247.7
240.1
283.7
265.0
260.2
GROUP I
Liver Wt. 11.428 12.216 14.081 13.395 11.981
Relative Liver to Body Wt. 0.046
0.051
0.050
0.051
0.046
Test Day
5 5 5 5
5
Animal
Number 627793
627797
627799
627800
627808
Final
Body Wt. 283.5
324.2
294.7
331.3
321.8
GROUP II
Liver Wt.
15.292 15.803 14.285 16.344 17.580
Relative Liver
to Body Wt. 0.054
0.049
0.048
0.049
0.055
Test Day
10 10
10
10 10
Animal Number 627796
627806
627807
627809
627816
Final
Body Wt. 322.7
320.3
305.2
336.2
330.2
GROUP III
Liver Wt. 13.404 15.413
14.935 14.967 15.811
Relative Liver to Body Wt. 0.042
0.048
0.049
0.045
0.048
Test Day
13 13
13 13 13
24-
Company Sanitized. Does not contain TSCA CBI
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
CORN OIL (NEGATIVE CONTROL)
INDIVII3UAL FINAL BODY WEIGHTS (g) , LIVER WEIGHTS (g ) , AND
RELATIVE LI\?ER TO BODY WE:[GHT OF MALE RATS
Animal Number 627791 627794
627804
627812
627817
Final
Body Wt. 365.6
416.7
378.1
388.4
407.3
GROUP IV
Liver Wt.
15.371 19.105 15.326 16.775 16.600
Relative Liver to Body Wt. 0.042
0.046
0.041
0.043
0.041
Test Day
24 24 24 24 24
Animal Number 627792
627798
627813
627814
627815
Final
Body Wt.
496.8
517.3
416.8
386.9
505.9
GROUP V
Liver Wt.
16.359 19.293 15.234 14.358 20.958
Relative Liver
to Body Wt. 0.033
0.037
0.037
0.037
0.041
Test Day
52 52
52 52
52
Animal Number 627795
627811
627819
627820
627821
Final
Body Wt.
485.0
511.6
653.1
618.0
521.5
GROUP VI
Liver Wt.
16.649 17.405 21.828 26.766 17.943
Relative Liver to Body Wt.
0.034 0.034 0.033 0.043 0.034
Test Day
94 94
94 94
94
-25-
Company Sanitized. Does not contain TSCA CBI
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
CORN OIL :ACETONE (NEGAT'IVE CONTROL)
INDIV'IDUAL FINAL BODY WEIGHTS (g), LIVER WEIGHTS (g ) , AND RELATIVE LI\rER TO BODY WEK3HT OF MALE RATS
Animal
Number 625361
625363
625364
625380
625383
Final
Body Wt. 349.7
286.7
312.0
305.5
313.1
GROUP I
Liver Wt. 16.800 11.236 13.845 13.253 13.026
Relative Liver to Body Wt. 0.048
0.039
0.044
0.043
0.042
Test Day
5 5 5 5 5
Animal Number 625355
625362
625367
625368
625378
Final
Body Wt. 333.6
332.9
363.8
386.7
365.4
GROUP II
Liver Wt. 14.409 14.363 16.139 17.745 15.328
Relative Liver to Body Wt. 0.043
0.043
0.044
0.046
0.042
Test Day
10
10 10
10 10
Animal Number 625357 625358
625370
625384
625385
Final
Body Wt. 405.6
340.7
407.0
357.1
377.6
GROUP III
Liver Wt. 20.091 12.954 21.654 16.520 17.355
Relative Liver to Body Wt. 0.050 0.038 0.053
0.046
0.046
Test Day
13 13 13
13
13
.26-
Company Sanitized. Does not contain TSCA CB1
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
CORN 0:[L:ACETONE (NEGA^?IVE CONTROL)
IND IVIDUAL FINAL I30DY WEIGHTS (g), LIVER WEIGHTS (gf), AND
RELATIVE L IVER TO BODY WEI GHT OF MALE RATS
Animal
Number 625354
625365
625371
625376
625381
Final
Body Wt.
396.1
459.6
447.3
432.9
381.8
GROUP IV
Liver Wfc. 16.383 18.313 17.859
19.168 14.135
Relative Liver to Body Wt. 0.041
0.040
0.040
0.044
0.037
Test Day
24 24 24 24 24
Animal Number 625356
625359
625360
625372
625374
Final
Body Wt. 533.7
530.3
555.4
506.2
512.3
GROUP V
Liver Wt. 20.498 22.901 23.312 21.287 18.378
Relative Liver to Body Wt. 0.038
0.043
0.042
0.042
0.036
Test Day
52
52
52 52 52
Animal Number 625353
625369
625373
625375
625377
Final
Body Wt. 565.3
514.8
673.7
588.8
496.6
GROUP VI
Liver Wt.
18.655 17.379 20.073 18.869 17.261
Relative Liver to Body Wt. 0.033
0.034
0.030
0.032
0.035
Test Day
94 94 94 94
94
-27-
Company Sanitized. Does not contain TSCA CB1
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
H-24,019 (POSITIVE (:ONTROL)
INDIVI DUAL FINAL B01DY WEIGHTS (g) , LIVER WEIGHTS (g ) , AND
RELATIVE Ll\^R TO BODY WEK3HT OF MALE RATS
Animal Number 625322
625323
625336
625343
625349
Final
Body Wt. 329.0
298.0
318.1
294.0
293.7
GROUP I
Liver Wt.
16.409 14.830 16.545 13.809 15.685
Relative Liver to Body Wt. 0.050
0.050
0.052
0.047
0.053
Test Day
5 5 5 5 5
Animal
Number 625320
625330
625332
625341
625350
Final
Body Wt. 312.1
310.1
318.3
325.6 .
284.3
GROUP II
Liver Wt. 18.845 16.343 17.528 18.254 15.709
Relative Liver to Body Wt. 0.060
0.053
0.055
0.056
0.055
Test Day
10 10 10
10 10
Animal
Number 625321
625327
625342
625345 625348
Final
Body Wt. 371.2
355.3
324.4
336.9
336.4
GROUP III
Liver Wt.
22.322 22.259 20.718 24.403 20.541
Relative Liver to Body Wt. 0.060
0.063
0.064
0.072
0.061
Test Day
13 13
13 13 13
-28-
Company Sanitized. Does not contain TSCA CB1
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
H-2<1019 (POSITIVE <SONTROL)
INDI VIDUAL FINAL BODY WEIGHTS (g), LIVER WEIGHTS (g ) , AND RELATIVE LI\n3R TO BODY WEHGHT OF MALE RATS
Animal
Number 625325 625328
625338
625340
625352
Final
Body Wt. 381.3
423.9
339.9
419.0
375.3
GROUP IV
Liver Wt. 21.479 22.100 18.018 23.131 21.835
Relative Liver to Body Wt.
0.056 0.052 0.053 0.055 0.058
Test Day
24 24 24 24 24
Animal Number 625324
625329
625333
625334
625344
Final
Body Wt. 447.4
498.1
427.4
426.5
391.0
GROUP V
Liver Wt. 20.900 20.911 20.508 19.144 17.666
Relative Liver to Body Wt. 0.047
0.042
0.048
0.045
0.045
Test Day
52 52 52
52 52
Animal Number 625326 625335
625346
626347
625351
Final
Body Wt. 577.5
579.5
556.9
638.9
636.8
GROUP VI
Liver Wt. 23.749 21.548 23.945 27.416 25.615
Relative Liver to Body Wt. 0.041
0.037
0.043
0.043
0.040
Test Day
94 94 94 94
94
Company Sanitized. Does nc contain TSCA CBI 29-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
H-2^1020 (POSITIVE C ONTROL)
INDIV'1DUKL FINAL BODY WEIGHTS (g) , LIVER WEIGHTS (g ) ,
RELATIVE LI\?ER TO BODY WEIG HT OF MALE RATS
AND
Animal Number 627756
627767
627771
627773
627777
Final
Body Wt. 237.5
248.6
239.6
262.3
236.0
GROUP I
Liver Wt. 15.360 19.033 16.968 17.629 16.268
Relative Liver to Body Wt.
0.065
0.077
0.071
0.067
0.069
Test Day
5 5 5 5 5
Animal
Number 627768
627774
627776
627782
627785
Final
Body Wt.
293.5
338.2
254.4
268.2
267.9
GROUP II
Liver Wt.
22.536 27.332 18.821 20.172 20.857
Relative Liver to Body Wt. 0.077
0.081
0.074
0.075
0.078
Test Day
10
10 10
10 10
Animal Number 627758
627763
627764
627787
627788
Final
Body Wt.
308.7
285.8
306.7
234.9
309.4
GROUP III
Liver Wt.
26.021 22.123 21.526 16.498 22.730
Relative Liver to Body Wt.
0.084
0.077
0.070
0.070
0.073
Test Day
13 13
13 13 13
-30-
Company Sanitized. Does not contain TSCA CB1
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
H-241020 (POSITIVE iCONTROL)
INDI^'IDUMj FINAL BODY WEIGHTS (g), LIVER WEIGHTS (g ) , AND
RELATIVE LI\?ER TO BODY WEIiGHT OF MALE RATS
Animal Number 627759
627761
627770
627779
627786
Final
Body Wt. 380.1
359.4
379.8 406.2
326.1
GROUP IV
Liver Wt. 22.707 19.579 19.540 24.858 16.410
Relative Liver to Body Wt. 0.060
0.054
0.051
0.061
0.050
Test Day
24 24
24 24
24
Animal Number 627757
627760
627765
627772
627781
Final
Body Wt. 436.7
456.5
455.6
513.5
421.0
GROUP V
Liver Wt. 16.899 18.240
16.505 20.225 16.695
Relative Liver to Body Wt.
0.039
0.040 0.036
0.039 0.040
Test Day
52
52 52
52 52
Animal Number 627762
627769
627775
627778 627783
Final
Body Wt. 528.6
609.6
552.8
445.3
557.2
GROUP VI
Liver Wt. 17.732 19.324 17.296
15.628 21.044
Relative Liver to Body Wt.
0.034
0.032
0.031
0.035
0.038
Test Day
94 94 94
94 94
Company Sanitized. Does not contain TSCA CB1 31-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
H-24159 (TEST SUBSTANCE)
INDIVIDUAL FINAL BODY WEIGHTS (g), LIVER WEIGHTS (g) / AND
RELATIVE LIVER TO BODY WEIGHT OF MALE RATS
Animal Number 628162
628173
628176 628183
628186
Final
Body Wt.
271.8
269.1
254.2
298.4
231.5
GROUP I
Liver Wt.
12.989 14.117 12.659 15.958 10.912
Relative Liver to Body Wt. 0.048
0.052
0.050
0.053
0.047
Test Day
5 5 5 5 5
Animal Number 628159
628165
628168
628172
628177
Final
Body Wt. 299.3
300.1
313.0
281.8
322.5
GROUP II
Liver Wt. 14.843 15.557 13.711 13.779 15.930
Relative Liver
to Body Wt. 0.050
0.052
0.044
0.049
0.049
Test Day
10 10 10 10
10
Animal
Number 628154
628158
628171
628175
628185
Final
Body Wt. 338.9
332.7
320.6
326.5
296.1
GROUP III
Liver Wt. 16.428 16.667 14.018 14.365
14.443
Relative Liver to Body Wt. 0.048
0.050
0.044
0.044
0.049
Test Day
13 13
13 13
13
company Sanitized. Does not contain TSCA CBI 32-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
H- 24159 (TEST SUBSTANCE) INDIVI DUAL FINAL B(3DY WEIGHTS (g), LIVER WEIGHTS (g ) , AND
RELATIVE LI VER TO BODY WEI GHT OF MALE RATS
Animal
Number 628155
628164
628166
628170
628184
Final
Body Wt.
412.0
386.4
417.1
421.1
376.2
GROUP IV
Liver Wt. 18.626 18.622 18.295 18.890 16.289
Relative Liver to Body Wt. 0.045
0.048
0.044
0.045
0.043
Test Day
24 24
24 24
24
Animal Number 628156
628157
628160
628180
628181
Final
Body Wt. 475.5
532.7
474.3
508.1
450.8
GROUP V
Liver Wt.
18.319 20.768 17.939 17.447 14.735
Relative Liver to Body Wt.
0.039
0.039
0.038
0.034
0.033
Test Day
52 52 52
52
52
Animal Number 628161
628167
628174
628178
628179
Final
Body Wt.
503.0
635.7
571.7
541.9
629.8
GROUP VI
Liver Wt. 18.991 22.640 20.463 19.841 23.497
Relative Liver to Body Wt.
0.038 0.036 0.036 0.037
0.037
Test Day
94 94 94 94 94
Company Sanitized. Does not contain TSCA CBI 33-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
APPENDIX B Individual Fluorine Levels
company Sanitized. Does not contain TSCA CB1 -34-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
Terms: Active % Active
Mol Wt Active
Formulation Dose % P in Active
Mol Wt F
TERMS AND CALCULATIONS
Fluorine containing compound The % of formulation that is made up of fluorine containing components The molecular weight of the fluorine containing components (g/mole) The mg of formulation given per kg of animal body weight The % fluorine in the fluorine containing components of the formulation (weight basis) The molecular weight of fluorine g/mol
Compound Calculations:
Dose Active (mg/kg)
The mg of fluorine containing compound administered per kg of animal body weight.
= (% active/100) x Formulation Dose
Dose Active (mmole/kg)
The mmole of fluorine containing compound administered per kg of animal body weight
= dose [mg/kg] / Mol Wt Active [mg/mmol]
Dose F (mg/kg)
The mg Fluorine administered per kg of animal body weight = (% F in active/100) x Dose Active [mg/kg]
Dose F (mmol/kg)
The mmole of fluorine administered per kg of animal body weight = Dose F [mg/kg] / Mol Wt F [mg/mmol]
Molar Ratio (Active/F)
The moles of fluorine containing compound per mole of fluorine = Dose Active [mmol/kg] / Dose F [mmol/kg]
Formulation Dose Normalization Factor
The formulation dose that would be required to administer the amount of active needed to achieve the normalized dose
= (Normalized dose of Active [mmol/kg] / Dose Active [mmol/kg]) x Formulation Dose
-35-
impany Sanitized. Does not contain TSCA CBI
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
TERMS AND CALCULATIONS
Individual Animal Measurement:
ppm F in liver
The ppm fluoride measured in liver
Individual Animal Calculations:
ppm F in Liver minus Bkg 0.2 ppm
The ppm fluoride measured in liver minus the background fluoride measured in control animal liver. In this case the value was established at 0.2 ppm.
ppm F in Liver normalized to 0.1 mmol/kgDose
The ppm fluoride minus background that would be expected if the active dose was 0.1 mmol/kg instead of the actual active dose. This
assumes linearity between administered dose and liver fluorine levels,
but is needed because different doses of active were used in the study. = ( 0.1 [mmol/kg] / Active dose [mmol/kg]) x (ppm F in liver minus background)
fimolar equivalents of active in liver
The jumolar [/xmol/L] concentration of fluorine containing compound
in liver based on the ppm fluorine in liver normalized to 0.1 mmol/kg active dose. This assumes that all liver fluorine is derived from the fluorine-containing component in the formulation. Note: 1 ppm -
Img/L = (Normalized ppm [mg/L] fluorine in liver / Mol Wt F
[mg/mmol]) x molar ratio active/F [mmol active/mmol F] x 1000 ^mol/mmol
ompany Sanitized. Does not contain TSCA CB1 36-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-4182 Supplement No. 1
_____FACTORS INFLUENCING INTERPRETATION OF KINETIC ANALYSIS_____
Considerations:
- The data used for kinetic analysis was from a limited screen and extrapolation should be done cautiously.
- Sample size is low - Analytical data used without validation - Steady-state not reached - Terminal phase may not be reached - Some compounds are mixtures of fluorinated compounds - Different active and formulation doses were used - Different vehicles were used to deliver formulations - Each compound may have very different potency for producing toxicity
Assumptions: (May or may not be justified in all cases)
- Liver fluorine concentrations are linear with respect to dose - Analytical method is appropriate for all types of compounds - Elimination kinetics can be determined based on total fluorine rather than on concentrations of
individual components - Background Fluorine is 0.2 ppm - % F data is the % Fluorine of the active (Fluorine containing component(s) in the formulation) - Molecular weight is the molecular weight of the active component in the formulation
.37-
-?mpany Sanitized. Does not contain TSCA CBI
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
Data for H- 24019
DuPont-4182 Supplement No. 1
Given:
Mol Wt. Active (g/mole):
497
Formulation Dose (mg/kg):
10
% Active (F Containing) in Formulation: 100
% F in Active:
65
Mol Wt. F (g/mol):
19
Calculated Values: Dose Active (mg/kg): Dose Active (mmole/kg): Formulation Dose Normalization Factor:
10
0.020 49.7
Dose F (mmol/kg):
0.342
Molar Ratio (Active/F): 0.059
Dose F (mg/kg):_____6.5
Rat Number
Test Day Sample
ppmF
in
Liver
Group II
625320
10
319.4
625330
10
355.4
625332
10
338.4
625341
10
305.0
625350
10
322.7
Group VI
625326
94
625335
94
625346
94
625347
94
625351
94
79.8 89.6 73.8 62.5 82.1
ppm F in Liver
Minus Bkg 0.2 ppm
319.2 355.2 338.2 304.8 322.5
79.6 89.4 73.6 62.3 81.9
ppm F in Liver Normalized to 0.1 mmoles/kg
Dose
1586.42 1765.34 1680.85 1514.86 1602.83
395.61 444.32 365.79 309.63 407.04
/xmolar Equivalents of Active in
Liver
4910.77 5464.62 5203.08 4689.23 4961.54
1224.62 1375.38 1132.31 958.46 1260.00
-38-
3omoanv SaniHzpd. "o<"s "<'* /;""^" TRF.R r^l
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
Data for H- 24020
DuPont-4182 Supplement No. 1
Given:
Mol Wt. Active (g/mole):
426
Formulation Dose (mg/kg):
20
% Active (F Containing) in Formulation: 100
% F in Active:
69
Mol Wt. F (g/mol):
19
Calculated Values: Dose Active (mg/kg): Dose Active (mmole/kg):
Formulation Dose Normalization Factor:
20 0.047 42.6
Dose F (mmol/kg):
0.726
Molar Ratio (Active/F): 0.065
Dose F (mg/kg):_____13.8
Rat Number
Test Day Sample
ppmF
in
Liver
Group II
627768
10
627774
10
627776
10
627782
10
627785
10
182.5 109.0 174.0 147.5 165.8
Group VI
627778
94
1.9
627783
94
1.2
627762
94
1.9
627775
94
1.6
627769
94
1.8
ppm F in Liver
Minus Bkg 0.2 ppm
182.3 108.8 173.8 147.3 165.6
1.7 1.0 1.7 1.4 1.6
ppm F in L iver
Normalize)jto
0.1 mmoles/kg Dose
388.30 231.74 370.19 313.75 352.73
3.62 2.13 3.62 2.98 3.41
fimoiar Equivalents of Active in
Liver
1321.01 788.41
1259.42 1067.39 1200.00
12.32 7.25
12.32 10.14 11.59
company Sanitized. Does not contain TSCA CB1 39-
H-24159: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
Data for H-24159
DuPont-4182 Supplement No. 1
Given:
Mol Wt. Active (g/mole):
450
Formulation Dose (mg/kg):
35
% Active (F Containing) in Formulation: 29
% F in Active:
55
Mol Wt. F (g/mol):
19
Calculated Values: Dose Active (mg/kg): Dose Active (mmole/kg): Formulation Dose Normalization Factor:
10.15 0.023 155.2
Dose F (mmol/kg):
0.294
Molar Ratio (Active/F): 0.077
Dose F (mg/kg):_____5.5825
Rat Number
Test Day Sample
ppmF
in
Liver
Group II
628177
10
88.4
628168
10
91.9
628165
10
81.8
628172
10
104.1
628159
10
86.2
Group VI
628178
94
3.9
628167
94
6.6
628161
94
4.8
628179
94
4.9
628174
94
6.2
ppm F in Liver
Minus Bkg 0.2 ppm
88.2 91.7 81.6 103.9 86.0
3.7 6.4 4.6 4.7 6.0
ppm F in Liver Normalized to 0.1 mmoles/kg
Dose
391.03 406.55 361.77 460.64 381.28
16.40 28.37 20.39 20.84 26.60
/imolar Equivalents of Active in
Liver
1579.94 1642.63 1461.71 1861.17 1540.53
66.28 114.64 82.40 84.19 107.48
'ampany Sanitized. Does not contain TSCACBt -40-